{"id":48971,"date":"2022-09-29T14:02:08","date_gmt":"2022-09-29T12:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/"},"modified":"2022-09-29T14:02:08","modified_gmt":"2022-09-29T12:02:08","slug":"prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/","title":{"rendered":"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer"},"content":{"rendered":"
\n

NAARDEN, Netherlands & WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V.<\/a>, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, today announced the appointment of Anne Sullivan as Chief Business Officer. In this role, Ms. Sullivan will lead all strategic collaboration activities.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cAs Prilenia prepares for key milestones in its pipeline over the coming months, we believe Anne brings tremendous experience and perspective to our leadership team,\u201d said Dr. Michael R. Hayden, CEO and Founder of Prilenia. \u201cWe are delighted to welcome Anne to the team and are confident that her strong background in neurology and expertise in corporate and business development will be invaluable as Prilenia takes important steps toward its future.\u201d\n<\/p>\n

\n\u201cPrilenia represents an organization truly committed to scientific rigor as well as to people living with serious neurological diseases, like Huntington\u2019s disease and ALS, and I couldn\u2019t be more pleased to join the team and advance its mission,\u201d said Anne Sullivan, Chief Business Officer at Prilenia. \u201cPrilenia is poised to make significant progress over the next few quarters, with the Company expecting key data from its ongoing studies of pridopidine in ALS and Huntington\u2019s disease. Knowing that many people are waiting for potential new therapeutic options, we are actively evaluating opportunities to accelerate and expand the potential impact of pridopidine.\u201d\n<\/p>\n

\nAnne brings more than 25 years of experience in the biopharmaceutical industry. Prior to joining Prilenia, Anne served as Chief Business Officer at Rodin Therapeutics, a privately held clinical stage biopharmaceutical company discovering and developing first-in-class therapeutics for serious neurological diseases. Anne played an instrumental role in the acquisition of Rodin by Alkermes plc in November 2019 and has since then served as consulting CBO for multiple private and public biopharma companies. Before joining Rodin, Anne served as Senior Vice President, Corporate Development & Operations at Sea Pharmaceuticals, LLC, and Vice President, Corporate Development and Licensing with Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). She began her career as a certified public accountant working in audit and international finance with KPMG and Wang Laboratories. Anne received an A.B. in economics\/accounting from the College of the Holy Cross and an MBA from the Tuck School of Business at Dartmouth College.\n<\/p>\n

\nAbout Prilenia<\/b>\n<\/p>\n

\nPrilenia is a clinical stage biotech startup founded in 2018 focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders.\n<\/p>\n

\nThe Company\u2019s lead asset, pridopidine, is an oral, highly selective Sigma-1 Receptor agonist that is currently being assessed in clinical studies as a potential treatment option for people living with Huntington\u2019s disease (HD) as well as ALS.\n<\/p>\n

\nPrilenia is backed by a group of well-respected investors including: Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Waltham, Mass. in the U.S.\n<\/p>\n

\nFor more information visit www.prilenia.com<\/a> and follow us on LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

\n\u00a9<\/sup>2022 Prilenia Therapeutics B.V.\n<\/p>\n

\nFor a copy of this release, visit Prilenia\u2019s website at www.prilenia.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPrilenia<\/b>
Kristina Coppola
\n
Head of Corporate Communications
\n
info@prilenia.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NAARDEN, Netherlands & WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, today announced the appointment of Anne Sullivan as Chief Business Officer. In this role, Ms. Sullivan will lead all strategic collaboration activities. \u201cAs Prilenia … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48971","6":"format-standard","7":"category-industry"},"yoast_head":"\nPrilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NAARDEN, Netherlands & WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, today announced the appointment of Anne Sullivan as Chief Business Officer. In this role, Ms. Sullivan will lead all strategic collaboration activities. \u201cAs Prilenia ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T12:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220928006018\/en\/1586184\/21\/AnneSullivan_PrileniaCBO_September2022.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer\",\"datePublished\":\"2022-09-29T12:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/\"},\"wordCount\":547,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006018\\\/en\\\/1586184\\\/21\\\/AnneSullivan_PrileniaCBO_September2022.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/\",\"name\":\"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006018\\\/en\\\/1586184\\\/21\\\/AnneSullivan_PrileniaCBO_September2022.jpg\",\"datePublished\":\"2022-09-29T12:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006018\\\/en\\\/1586184\\\/21\\\/AnneSullivan_PrileniaCBO_September2022.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006018\\\/en\\\/1586184\\\/21\\\/AnneSullivan_PrileniaCBO_September2022.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/","og_locale":"en_US","og_type":"article","og_title":"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer - Pharma Trend","og_description":"NAARDEN, Netherlands & WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, today announced the appointment of Anne Sullivan as Chief Business Officer. In this role, Ms. Sullivan will lead all strategic collaboration activities. \u201cAs Prilenia ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-29T12:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220928006018\/en\/1586184\/21\/AnneSullivan_PrileniaCBO_September2022.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer","datePublished":"2022-09-29T12:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/"},"wordCount":547,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928006018\/en\/1586184\/21\/AnneSullivan_PrileniaCBO_September2022.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/","url":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/","name":"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928006018\/en\/1586184\/21\/AnneSullivan_PrileniaCBO_September2022.jpg","datePublished":"2022-09-29T12:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220928006018\/en\/1586184\/21\/AnneSullivan_PrileniaCBO_September2022.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220928006018\/en\/1586184\/21\/AnneSullivan_PrileniaCBO_September2022.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/prilenia-expands-leadership-team-appoints-anne-sullivan-as-chief-business-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48971"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48971\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}